In addition, we found previously that CAP could selectively kill triple negative breast cancer cells, and this type of breast cancers is featured by high cancer stemness (90), implicating the functionality of CAP in targeting cancer stem cells; and such a property can be used to rewire lineage switch caused by CAR-T cells against CD19 for prolonged therapeutic efficacy and reduced recurrence rate. The gene discussed is CD19; the disease is cancer.